DB16444InvestigationalVaccines
The UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components . The vaccine... The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the virus.
- Also known as
- UB-612 COVID-19 vaccine
- Code names
- UB-612
What you can answer from here — as of October 30, 2025
Which companies are running trials of UB-612 COVID-19, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account